echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Nat Commun: Phase 1 clinical trial results of Tofacitinib in the treatment of systemic lupus erythematosus

    Nat Commun: Phase 1 clinical trial results of Tofacitinib in the treatment of systemic lupus erythematosus

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The pathogenesis of systemic lupus erythematosus (SLE) involves a variety of disorders of innate and adaptive immune pathways


    Immune blood vessel

    Existing studies have shown that the risk of cardiovascular disease (CVD) and premature arteriosclerosis is significantly increased in systemic lupus erythematosus, especially in young women


    Cardiovascular

    The immune disorders of systemic lupus erythematosus are believed to play a prominent role in promoting premature atherosclerosis


    The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a basic signal cascade that is used by cells to respond to the effects of various cytokines and growth factors


    Existing studies have shown that in animal models of lupus, Janus kinase (JAK) inhibitor tofacitinib can improve clinical disease characteristics, immune disorders and vascular dysfunction


    Randomized, double-blind, placebo-controlled randomized, double-blind, placebo-controlled

    In this study, 30 subjects were randomized to receive tofacitinib (5 mg, twice a day) or placebo in a 2:1 interval


    Safety and tolerabilitySafety and tolerabilityClinical response and mechanism researchClinical response and mechanism research

    Outcome Scale of Disease Activity and Patient Report

    Disease Activity and Patient Reported Outcome Scales Disease Activity and Patient Reported Outcome Scales

    The results show that tofacitinib is safe in the treatment of systemic lupus erythematosus and meets the primary endpoint of the study


    tofacitinib in the treatment of systemic lupus erythematosus in the process of security tofacitinib is safe in the treatment of systemic lupus erythematosus in the process of change good with systemic lupus erythematosus atherosclerosis-related cardiac metabolic and immunological parameters premature to change the good and the system lupus erythematosus premature atherosclerosis-related cardiac metabolic and immunological parameters of cholesterol in a subject STAT4 risk allele is more powerful in the risk allele of STAT4 have a more powerful subjects

     

    Original source:

    Original source:

    Sarfaraz A.


    Sarfaraz A.


     

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.